CD274 and non-small cell lung carcinoma: The PACIFIC trial was a randomized, placebo‐controlled, double‐blinded, multicenter analysis of 713 locally advanced NSCLC patients which found that durvalumab consolidation significantly enhanced PFS following CRT regardless of PD‐L1 expression status (median PFS: 16.8 months vs. 5.6 months; hazard ratio [HR] = 0.52, 95% CI: 0.42–0.65, P < 0.001).